Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,720.80
(
0.00%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.33
(
-0.10%
)
Bitcoin
70,997.00
(
1.57%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 164640

Monday, 07/29/2013 11:47:49 PM

Monday, July 29, 2013 11:47:49 PM

Post# of 257262

VRTX management said during Q&A that the results in the 200mg PK studies of VX-135 compared favorably with the results seen for sofosbuvir at 400mg. Is that not a fair statement?

It might be fair, but it’s essentially meaningless. PK studies are not demonstrations of efficacy.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now